Novel highly potent and selective nonsteroidal aromatase inhibitors: Synthesis, biological evaluation and structure-activity relationships investigation

Journal of Medicinal Chemistry

Volumn 53, Issue 14, 2010, Pages 5347-5351

  Gobbi, Silvia ^a   Zimmer, Christina ^b   Belluti, Federica ^a   Rampa, Angela ^a   Hartmann, Rolf W ^b   Recanatini, Maurizio ^a   Bisi, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; FADROZOLE; KETOCONAZOLE;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AROMATASE INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; MICROSOMES; MOLECULAR CONFORMATION; PLACENTA; PREGNANCY; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOXANTHENES; XANTHONES;

EID: 77954735637     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100319h     Document Type: Article

References (30)

1. Cancer Facts & Figures 2009; American Cancer Society: Atlanta, GA, 2010.
2. Sasano, H.; Miki, Y.; Nagasaki, S.; Suzuki, T. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology Pathol. Int. 2009, 59, 777-789
3. Santen, R. J.; Brodie, H.; Simpson, E. R.; Siiteri, P. K.; Brodie, A. History of aromatase: saga of an important biological mediator and therapeutic target Endocr. Rev. 2009, 30, 343-375
4. Wong, Z. W.; Ellis, M. J. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br. J. Cancer 2004, 90, 20-25
5. Needleman, S. J.; Tobias, J. S. Aromatase inhibitors in early hormone receptor-positive breast cancer: what is the optimal initiation time for the maximum benefit? Drugs 2008, 68, 1-15
6. Yahiaoui, S.; Fagnere, C.; Pouget, C.; Buxeraud, J.; Chulia, A. J. New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation Bioorg. Med. Chem. 2008, 16, 1474-1480
7. Jackson, T.; Woo, L. W.; Trusselle, M. N.; Purohit, A.; Reed, M. J.; Potter, B. V. Nonsteroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling ChemMedChem 2008, 3, 603-618
8. Lézé, M. P.; Palusczak, A.; Hartmann, R. W.; Le Borgne, M. Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4713-4715
9. Balunas, M. J.; Su, B.; Riswan, S.; Fong, H. H.; Brueggemeier, R. W.; Pezzuto, J. M.; Kinghorn, A. D. Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae) Phytochem. Lett. 2009, 2, 29-33
10. Bubert, C.; Woo, L. W.; Sutcliffe, O. B.; Mahon, M. F.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4 H -1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities ChemMedChem 2008, 3, 1708-1730
11. Woo, L. W.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K. R.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template (dagger) J. Med. Chem. 2010, 53, 2155-2170
12. Gobbi, S.; Cavalli, A.; Bisi, A.; Recanatini, M. From nonsteroidal aromatase inhibitors to multifunctional drug candidates: classic and innovative strategies for the treatment of breast cancer Curr. Top. Med. Chem. 2008, 8, 869-887
13. Recanatini, M.; Bisi, A.; Cavalli, A.; Belluti, F.; Gobbi, S.; Rampa, A.; Valenti, P.; Palzer, M.; Palusczak, A.; Hartmann, R. W. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17alpha-hydroxylase/C17,20-lyase J. Med. Chem. 2001, 44, 672-680
14. Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R. W.; Recanatini, M. Enantioselective Nonsteroidal Aromatase Inhibitors Identified through a Multidisciplinary Medicinal Chemistry Approach J. Med. Chem. 2005, 48, 7282-7289
15. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780
16. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors J. Med. Chem. 2007, 50, 3420-3422
17. Pinto, M. M. M.; Sousa, M. E.; Nascimento, M. S. J. Xanthone derivatives: new insights in biological activities Curr. Med. Chem. 2005, 12, 2517-2538
18. Na, Y. Recent cancer drug development with xanthone structures J. Pharm. Pharmacol. 2009, 61, 707-712
19. Da Re, P.; Valenti, P.; Primofiore, G.; Cima, L. Structure-activity relationships in centrally stimulating xanthone derivatives. Part VII. Some new basic xanthone derivatives Chim. Ther. 1973, 1, 60-64
20. Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Calveley, S. B.; Denny, W. A. Potential antitumor agents. 58. Synthesis and Structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo J. Med. Chem. 1989, 32, 793-799
21. Rampa, A.; Chiarini, A.; Bisi, A.; Budriesi, R.; Valenti, P. 4-heterotricyclic substituted 1,4 dihydropyridines with a potent selective bradycardic effect Arzneim. Forsch. 1991, 41, 705-709
22. Rewcastle, G. W.; Atwell, G. J.; Palmer, B. D.; Boyd, P. D. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9 H -xanthene-4-acetic acid J. Med. Chem. 1991, 34, 491-496
23. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids J. Med. Chem. 1990, 33, 1375-1379
24. Thompson, E. A., Jr.; Siiteri, P. K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione J. Biol. Chem. 1974, 249, 5364-5372
25. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent nonsteroidal CYP17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme J. Enzyme Inhib. 2004, 19, 17-32
26. Njar, V. C.; Brodie, A. M. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors Drugs 1999, 58, 233-255
27. Harris, K. A.; Weinberg, V.; Bok, R. A.; Kakefuda, M.; Small, E. J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer J. Urol. 2002, 168, 542-545
28. Eklund, J.; Kozloff, M.; Vlamakis, J.; Starr, A.; Mariott, M.; Gallot, L.; Jovanovic, B.; Schilder, L.; Robin, E.; Pins, M.; Bergan, R. C. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer Cancer 2006, 106, 2459-2465
29. Balunas, M. J.; Su, B.; Brueggemeier, R. W.; Kinghorn, A. D. Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity J. Nat. Prod. 2008, 71, 1161-1166
30. Strehlke, P.; Kessler, H. J.; Redmann, U. U.S. Patent 4006243, 1977.